Literature DB >> 21439476

Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.

Claude Haan1, Catherine Rolvering, Friedrich Raulf, Manuela Kapp, Peter Drückes, Gebhard Thoma, Iris Behrmann, Hans-Günter Zerwes.   

Abstract

Genetic deficiency of Jak3 leads to abrogation of signal transduction through the common gamma chain (γc) and thus to immunodeficiency suggesting that specific inhibition of Jak3 kinase may result in immunosuppression. Jak1 cooperates with Jak3 in signaling through γc-containing receptors. Unexpectedly, a Jak3-selective inhibitor was less efficient in abolishing STAT5 phosphorylation than pan-Jak inhibitors. We therefore explored the roles of Jak1 and Jak3 kinase functionality in signaling using a reconstituted system. The presence of kinase-inactive Jak1 but not kinase-inactive Jak3 resulted in complete abolishment of STAT5 phosphorylation. Specific inhibition of the "analog-sensitive" mutant AS-Jak1 but not AS-Jak3 by the ATP-competitive analog 1NM-PP1 abrogated IL-2 signaling, corroborating the data with the selective Jak3 inhibitor. Jak1 thus plays a dominant role over Jak3 and these data challenge the notion that selective ATP-competitive Jak3 kinase inhibitors will be effective.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21439476     DOI: 10.1016/j.chembiol.2011.01.012

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  74 in total

1.  Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.

Authors:  Rita Andraos; Zhiyan Qian; Débora Bonenfant; Joëlle Rubert; Eric Vangrevelinghe; Clemens Scheufler; Fanny Marque; Catherine H Régnier; Alain De Pover; Hugues Ryckelynck; Neha Bhagwat; Priya Koppikar; Aviva Goel; Lorenza Wyder; Gisele Tavares; Fabienne Baffert; Carole Pissot-Soldermann; Paul W Manley; Christoph Gaul; Hans Voshol; Ross L Levine; William R Sellers; Francesco Hofmann; Thomas Radimerski
Journal:  Cancer Discov       Date:  2012-05-03       Impact factor: 39.397

2.  Comment on: "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modelling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection".

Authors:  Nuggehally R Srinivas
Journal:  Clin Pharmacokinet       Date:  2015-12       Impact factor: 6.447

3.  Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.

Authors:  Shannon L Maude; Sibasish Dolai; Cristina Delgado-Martin; Tiffaney Vincent; Alissa Robbins; Arthavan Selvanathan; Theresa Ryan; Junior Hall; Andrew C Wood; Sarah K Tasian; Stephen P Hunger; Mignon L Loh; Charles G Mullighan; Brent L Wood; Michelle L Hermiston; Stephan A Grupp; Richard B Lock; David T Teachey
Journal:  Blood       Date:  2015-02-02       Impact factor: 22.113

4.  Regulation of Voltage-Gated K+ Channel Kv1.5 by the Janus Kinase JAK3.

Authors:  Jamshed Warsi; Bernat Elvira; Rosi Bissinger; Zohreh Hosseinzadeh; Florian Lang
Journal:  J Membr Biol       Date:  2015-06-23       Impact factor: 1.843

Review 5.  Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy.

Authors:  Thomas A Waldmann; Jing Chen
Journal:  Annu Rev Immunol       Date:  2017-02-09       Impact factor: 28.527

6.  Monomethylarsonous acid (MMA+3) Inhibits IL-7 Signaling in Mouse Pre-B Cells.

Authors:  Peace C Ezeh; Huan Xu; Fredine T Lauer; Ke Jian Liu; Laurie G Hudson; Scott W Burchiel
Journal:  Toxicol Sci       Date:  2015-10-30       Impact factor: 4.849

7.  Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.

Authors:  Henrik M Hammarén; Anniina T Virtanen; Bobin George Abraham; Heidi Peussa; Stevan R Hubbard; Olli Silvennoinen
Journal:  J Allergy Clin Immunol       Date:  2018-08-06       Impact factor: 10.793

8.  Network pharmacology of JAK inhibitors.

Authors:  Devapregasan Moodley; Hideyuki Yoshida; Sara Mostafavi; Natasha Asinovski; Adriana Ortiz-Lopez; Peter Symanowicz; Jean-Baptiste Telliez; Martin Hegen; James D Clark; Diane Mathis; Christophe Benoist
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-11       Impact factor: 11.205

9.  Environmentally relevant concentrations of arsenite and monomethylarsonous acid inhibit IL-7/STAT5 cytokine signaling pathways in mouse CD3+CD4-CD8- double negative thymus cells.

Authors:  Huan Xu; Fredine T Lauer; Ke Jian Liu; Laurie G Hudson; Scott W Burchiel
Journal:  Toxicol Lett       Date:  2016-02-24       Impact factor: 4.372

10.  Janus kinase 1/3 signaling pathways are key initiators of TH2 differentiation and lung allergic responses.

Authors:  Shigeru Ashino; Katsuyuki Takeda; Hui Li; Vanessa Taylor; Anthony Joetham; Polly R Pine; Erwin W Gelfand
Journal:  J Allergy Clin Immunol       Date:  2013-12-22       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.